Subjective cognitive decline and anxious/depressive symptoms during the COVID-19 pandemic: what is the role of stress perception, stress resilience, and β-amyloid?

Muge Akinci1,2†, Gonzalo Sánchez-Benavides1,3,4†, Anna Brugulat-Serrat1,3,4,5, Cleofé Peña-Gómez1, Eleni Palpatzis1,2, Mahnaz Shekari1,2,3,4, Carme Deulofeu1, Sherezade Fuentes-Julian1, Gemma Salvadó1,3,4,6, José María González-de-Echávarri1, Marc Suárez-Calvet1,3,4,7, Carolina Minguillón1,3,4, Karine Fauria1,4, José Luis Molinuevo1,8, Juan Domingo Gispert1,2,3,9, Oriol Grau-Rivera1,3,4,7, Eider M. Arenaza-Urquijo1,3,4* and for the ALFA Study

Abstract
Background: The COVID-19 pandemic may worsen the mental health of people reporting subjective cognitive decline (SCD) and therefore their clinical prognosis. We aimed to investigate the association between the intensity of SCD and anxious/depressive symptoms during confinement and the underlying mechanisms.

Methods: Two hundred fifty cognitively unimpaired participants completed the Hospital Anxiety and Depression Scale (HADS) and SCD-Questionnaire (SCD-Q) and underwent amyloid-β positron emission tomography imaging with [18F] flutemetamol (N = 205) on average 2.4 (± 0.8) years before the COVID-19 confinement. During the confinement, participants completed the HADS, Perceived Stress Scale (PSS), Brief Resilience Scale (BRS), and an ad hoc questionnaire on worries (access to primary products, self-protection materials, economic situation) and lifestyle changes (sleep duration, sleep quality, eating habits). We investigated stress-related measurements, worries, and lifestyle changes in relation to SCD. We then conducted an analysis of covariance to investigate the association of SCD-Q with HADS scores during the confinement while controlling for pre-confinement anxiety/depression scores and demographics. Furthermore, we introduced amyloid-β positivity, PSS, and BRS in the models and performed mediation analyses to explore the mechanisms explaining the association between SCD and anxiety/depression.

Results: In the whole sample, the average SCD-Q score was 4.1 (± 4.4); 70 (28%) participants were classified as SCD, and 26 (12.7%) were amyloid-β-positive. During the confinement, participants reporting SCD showed higher PSS (p = 0.035) but not BRS scores (p = 0.65) than those that did not report SCD. No differences in worries or lifestyle changes were observed. Higher SCD-Q scores showed an association with greater anxiety/depression scores irrespective

†Muge Akinci and Gonzalo Sánchez-Benavides contributed equally to this work.
*Correspondence: earenaza@barcelonabeta.org
1 Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES), Madrid, Spain
Full list of author information is available at the end of the article

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
of pre-confinement anxiety/depression levels ($p = 0.002$). This association was not significant after introducing amyloid-β positivity and stress-related variables in the model ($p = 0.069$). Amyloid-β positivity and PSS were associated with greater HADS irrespective of pre-confinement anxiety/depression scores ($p = 0.023; p < 0.001$). The association of SCD-Q with HADS was mediated by PSS ($p = 0.01$).

**Conclusions:** Higher intensity of SCD, amyloid-β positivity, and stress perception showed independent associations with anxious/depressive symptoms during the COVID-19 confinement irrespective of pre-confinement anxiety/depression levels. The association of SCD intensity with anxiety/depression was mediated by stress perception, suggesting stress regulation as a potential intervention to reduce affective symptomatology in the SCD population in the face of stressors.

**Keywords:** Subjective cognitive decline, Stress, Anxiety, Depression, COVID-19 confinement, Alzheimer’s disease

**Background**

The COVID-19 pandemic and subsequent measures implemented to prevent the spread of the disease, such as home confinement, are having a global impact on the mental health of the general population [1, 2]. Several studies conducted during this period indicated that the mental health burden of the pandemic may be greater in clinically vulnerable populations [3–5] such as those with subjective cognitive decline (SCD) [6, 7].

During the preclinical stage, Alzheimer’s disease (AD) pathologies—amyloid beta (Aβ) and tau—slowly aggregate in the brain and interact with other risk factors including anxiety and depression [8–10], eventually leading to cognitive decline and dementia [11]. Before the onset of the cognitive impairment, some individuals may experience SCD defined as the perception of cognitive decline despite having objectively normal performance in neuropsychological testing [12, 13]. SCD is associated with a higher risk of developing AD [14, 15] as well as with the earliest AD-related pathophysiological processes such as Aβ accumulation [14, 16, 17].

Affective symptoms have been linked with an elevated risk for developing AD in cognitively unimpaired (CU) adults [8, 9, 18]. Moreover, growing evidence suggests associations between anxious/depressive symptoms and biomarkers of AD in CU older adults [19–21], such as with brain Aβ burden [22, 23]. These symptoms may also underlie SCD and/or interact with it [24]. Several studies reported that anxiety, depression, and worries are among the most common concurrent affective symptoms with SCD in older adults [24–26]. Moreover, the co-occurrence of SCD with these symptoms has been linked with an increased likelihood of cognitive decline [27–31].

Recent studies found associations between subjective memory complaints and stressful life events in CU older adults [32, 33]. COVID-19-related home confinement, as one of the main stressors related to the pandemic [33, 34], has been related to increased anxious/depressive symptoms as evidenced by numerous studies [1, 2, 34, 35]. Yet, many studies addressing this topic focused on the general population [1, 2] or individuals with dementia [4, 36]. Investigating the mental health implications of confinement in populations at elevated risk of cognitive decline can be instrumental to plan interventions and improve their clinical prognosis. In this regard, stress perception and stress resilience are especially interesting as they are shaped by individual factors or can be enhanced by training.

Herein, we focused on CU adults with a subgroup experiencing SCD, many of them being first-order descendants of sporadic AD patients and thus at a higher risk of developing cognitive decline and AD dementia [37, 38]. Our main aim was to investigate whether the intensity of SCD was associated with greater anxious/depressive symptoms during the COVID-19 confinement independent of pre-confinement anxiety/depression levels. Furthermore, we investigated the impact of brain Aβ status, stress perception, and stress resilience on these associations. Finally, we evaluated whether participants with or without SCD showed differences in worries and lifestyle changes during the confinement.

**Methods**

**Participants and study design**

Participants were selected from the longitudinal ALzheimer’s and FAamilies (ALFA+) study, nested to the ALFA parent cohort. ALFA parent cohort participants were recruited between 2013 and 2014 and included 2743 middle-aged (45–74 years) CU individuals, with the majority having a family history (FH) of sporadic AD [37]. The nested ALFA+ study included 451 cognitively intact participants (Clinical Dementia Rating $= 0$, Mini-Mental State Examination $\geq 27$, semantic fluency $\geq 12$) without any significant systematic illness, major psychiatric disorder, or unstable medical condition. ALFA+ participants underwent detailed cognitive testing, clinical interviews, lifestyle questionnaires, APOE genotyping, and blood and cerebrospinal fluid extractions, as well as magnetic resonance imaging and Aβ positron emission tomography (PET) data.
acquisitions [37]. These data were collected between 2016 and 2019 (average time lapse from ALFA+ HADS data acquisition to confinement data acquisition: 2.4 ± 0.8 years) from ALFA+ participants and referred to as “pre-confinement” measurements in the current study.

On May 8, 2020, during the COVID-19-related home confinement de-escalation periods in Spain [39], an invitation to participate in the current study was sent via an online link to 2582 participants of the ALFA parent cohort. Among these, 265 participants from the ALFA+ study responded positively to the invitation and completed an online assessment battery between May 8, 2020, and July 7, 2020, the period referred to as “confinement” in the present study. The assessment battery consisted of measurements of anxiety, depression, stress perception, stress resilience, and an ad hoc questionnaire developed to investigate specific worries and changes in lifestyle during the confinement. A total of 250 ALFA+ participants that completed the Hospital Anxiety and Depression Scale (HADS) in the assessment battery were included in the current study. As described below, participants had clinical data (SCD and HADS assessments) and $\alpha$PET data ($N = 205$) acquired during the pre-confinement period.

Clinical assessments

**SCD intensity and status**

During the pre-confinement period (in the context of the ALFA+ study), participants filled out the MyCog part of the Subjective Cognitive Decline-Questionnaire (SCD-Q) [40] before neuropsychological testing. The SCD-Q measures the presence or absence of a self-perceived deterioration in cognitive performance in the last two years of daily life. The MyCog part consists of 24 questions inquiring about the subjective experience of difficulties in performing memory, language, and executive tasks. Here, we investigated the intensity of SCD using MyCog scores as a continuous measurement of SCD symptoms, with higher scores indicating greater complaints in cognitive performance [26, 40]. The rationale behind this approach was based on the characteristic of our sample (middle-aged adults) and in consequence the relatively low percentage of participants classified as SCD with a binary classification (yes/no). Nevertheless, to allow comparison with previous and future research and test the between-group differences, we also classified participants as having SCD if the answer to the first question “Do you perceive memory or cognitive difficulties?” was affirmative and without SCD if the answer was negative [41]. Finally, we performed a sensitivity analysis with participants classified as SCD aged 60 and above.

**Anxiety and depression**

We used the 14-item HADS composed of the 7-item anxiety and the 7-item depression subscale to measure the symptoms of anxiety/depression. In each subscale, the items are scored from 0 to 3, generating a total score between 0 and 21. Higher scores indicate a greater level of anxiety or depression. The sum of 14 items generates a total anxiety/depression score [42].

**Stress perception and stress resilience**

Participants completed the 10-item Perceived Stress Scale (PSS) [43] as a measurement of self-reported stress perception during the confinement. Scores in the PSS range from 0 to 40 with higher ones reflecting a greater perception of stress. Furthermore, we evaluated the participants’ ability to resist or recover from stress using the 6-item Brief Resilience Scale (BRS) [44]. Higher scores in BRS indicate higher resilience to stress.

**Worries and lifestyle changes during the COVID-19 confinement**

We developed an ad hoc questionnaire that focused on the worries about access to primary products, self-protection materials, and economic situation, as well as changes in sleep duration, sleep quality, and eating habits during the confinement. The questions and the procedure to dichotomize the answers are provided in Additional file 1.

**Aβ PET data acquisition and pre-processing**

$[^{18}\text{F}]$ flutemetamol PET acquisitions were performed at the pre-confinement period in 205 participants in a Siemens Biograph mCT (Munich, Germany) following a cranial computed tomography scan for attenuation correction; 185 MBq (range 166.5–203.5 MBq) of $[^{18}\text{F}]$ flutemetamol was injected to the participants, and four frames of 5 min each were acquired 90 min post-injection. An OSEM3D algorithm with 8 iterations and 21 subsets was used for image reconstruction with point spread function and time-of-flight corrections into a matrix size of $1.02 \times 1.02 \times 2.03$ mm.

All PET images were preprocessed using SPM12 (Statistical Parametric Mapping, Welcome Trust Centre for Neuroimaging, UK; http://www.fil.ion.ucl.ac.uk/spm). The averaged PET images were co-registered to the corresponding T1-weighted images. Then, T1-weighted images were segmented and normalized to Montreal Neurological Institute (MNI) space alongside the PET images. The standardized value uptake ratio (SUVR) was calculated in MNI space from the bilateral frontal and parietotemporal areas, and the whole cerebellum was used as a reference region. We then converted
the SUVR values to the Centiloid (CL) [45] scale (see [46] for details). The cutoff value for CL was defined with a threshold of 12, and the scans were classified as “Aβ-negative” (< 12 CL) or “Aβ-positive” (≥ 12 CL) [46].

Statistical analyses
Descriptive statistics were generated with means and standard deviations for continuous variables and percentages and frequencies for categorical variables. We performed chi-square analyses to explore the differences in worries and lifestyle changes during the COVID-19 confinement between participants classified as SCD or without SCD.

We conducted analyses of covariance (ANCOVA) with HADS scores during the confinement as the dependent variable, adjusted by pre-confinement HADS scores. Firstly, we tested whether higher SCD-Q MyCog scores were associated with higher anxiety/depression scores during the confinement independent of the pre-confinement anxiety/depression levels. We adjusted the model by age, sex, years of education, and the inter-individual time variability between pre-confinement and confinement assessments. In the second step, we introduced Aβ positivity as well as stress perception (PSS) and stress resilience (BRS) in the model. Finally, we performed mediation analyses using bootstrap procedures (computed for N = 1000 bootstrapped samples) to investigate whether the tested association between SCD-Q and HADS scores was mediated by Aβ positivity or stress-related measurements.

Statistical analyses were conducted with IBM SPSS Statistics for Windows (Build 1.0.0.1447, Armonk, NY), and for the mediation analysis, the R Statistical Software (version 4.0.2) “mediation” package was used (R Foundation for Statistical Computing, Vienna, Austria). The results yielding a p value lower than 0.05 were considered as statistically significant.

Results
In the whole sample, participants’ age ranged from 52 to 72 years; 153 (61.2%) were women, and 248 (99.2%) were white Caucasians (0.8% Latinos). The average MyCog score was 4.1 (± 4.4) and 55 (22.3%) showed high-intensity SCD (MyCog scores ≥ 7) [47]. Seventy (28%) participants were classified as having SCD. A total of 197 participants (78.8%) and 53 of those classified as SCD (75.7%) had at least one parent diagnosed with sporadic AD. Twenty-six (12.7%) out of the 205 participants with available Aβ PET scans were Aβ-positive. Twenty-two (31.4%) of those classified as SCD sought medical help due to the perceived decline in cognitive abilities. During the confinement, 26 (10.4%) participants were diagnosed or under treatment for anxiety or depression. Table 1 displays the sociodemographic, clinical, and imaging data for the whole sample and participants classified as SCD vs. without SCD.

Aβ burden (measured with continuous CL) did not show any correlation with PSS (r = 0.13; p = 0.078) or BRS (r = 0.044; p = 0.53) scores. We did not find a correlation between PSS and BRS scores during the confinement (r = 0.058; p = 0.37).

Participants having SCD showed significantly higher MyCog scores than those without SCD (t_{249}=9.74; p < 0.001). Regarding anxiety/depression symptoms, we found a significant increase in HADS scores from pre-confinement to confinement (t_{249} = 4.04; p < 0.001) in the whole sample. Moreover, a lower frequency of going outside the home was associated with higher HADS scores during the confinement (F = 3.10; p = 0.017). This result suggests that the HADS evaluations are, at least partially, a reflection of the intensity of the COVID-19 confinement.

Participants with or without FH of sporadic AD did not present any difference in SCD-Q (t_{266} = -1.51; p = 0.14) or HADS scores (pre-confinement: t_{31.2} = -0.17; p = 0.87, during the confinement: t_{34.2} = 1.10; p = 0.29).

Differences in SCD status in pre-confinement anxiety/depression measurements and confinement-related stress perception and stress resilience
Participants classified as having SCD had higher pre-confinement HADS scores (p < 0.001) than those without SCD. Regarding stress-related measurements, participants with SCD showed higher PSS scores (t_{236} = 2.12; p = 0.035) during the confinement compared to those without SCD. No differences were found in BRS scores between the two groups (t_{246} = -0.45; p = 0.65).

In the whole sample, SCD-Q scores were positively correlated with pre-confinement HADS (r = 0.37; p < 0.001) and PSS (r = 0.43; p < 0.001) scores whereas they did not show any correlation with BRS scores (r = 0.044; p = 0.49).

Differences in SCD status in worries and lifestyle changes during the COVID-19 confinement
The results of the chi-square analyses investigating the differences between participants with and without SCD in confinement-related worries (access to primary products, self-protection materials, and economic situation) and lifestyle changes (sleep duration, sleep quality, and eating habits) are reported in Table 2. These analyses revealed that there were no significant differences between the two groups in any of the domains assessed (Fig. 1A).
Association between the intensity of SCD and anxiety/depression measurements

Higher SCD-Q MyCog scores were associated with greater HADS scores irrespective of the pre-confinement anxiety/depression levels. Furthermore, younger age, lower years of education, and having higher pre-confinement HADS scores showed independent associations with greater HADS scores during the confinement (Table 3).

Association between the intensity of SCD and anxiety/depression measurements: model including Aβ status and stress-related variables

Following the inclusion of Aβ positivity, PSS, and BRS in the model, SCD-Q MyCog scores did not show a significant association with HADS scores. Aβ positivity and PSS scores, instead, showed significant associations with higher HADS scores irrespective of the pre-confinement anxiety/depression levels. BRS scores were not associated with HADS scores. Additionally, sex (women) was associated with presenting greater HADS scores during the confinement (Table 4).
Mediation analyses
SCD-Q MyCog scores did not show a significant association with HADS scores after including Aβ status and stress-related variables in the model. Since both Aβ positivity and PSS were associated with HADS scores, we performed mediation analyses to investigate whether the effect of SCD-Q on anxiety/depression scores was mediated by Aβ positivity and/or stress perception. As illustrated in Fig. 2A, we found a significant partial mediation effect of stress perception on the association of SCD-Q MyCog scores with confinement HADS scores corresponding to 63% of the total association between the two variables ($B = 0.17$, 95% CI = 0.03 to 0.31, $p = 0.01$). Amyloid-β positivity, instead, did not show a mediating role between SCD-Q MyCog and HADS scores ($B = 0.02$, 95% CI = −0.01 to 0.06, $p = 0.45$, respectively, see Fig. 2B).

Sensitivity analyses
Models with SCD status
We repeated our main statistical analysis using the dichotomous SCD variable (participants classified as having SCD vs. without SCD) that is often used in the SCD field and in clinical practice [41]. The results showed that,
Table 3 Results from the model showing the association of SCD-Q with anxiety/depression scores

| Predictor                  | Confine HADS | B value (95% CI) | p value |
|----------------------------|--------------|------------------|---------|
| SCD-Q, MyCog scores       | 0.25 (0.096 to 0.41) | 0.002            |
| Age, years                | −0.19 (−0.33 to −0.055) | 0.006            |
| Sex (women)               | 1.25 (−0.12 to 2.63) | 0.074            |
| Education, years          | −0.31 (−0.50 to −0.12) | 0.001            |
| Pre-confinement HADS      | 0.42 (0.27 to 0.56) | < 0.001          |
| Time difference            | 0.38 (−0.26 to 1.03) | 0.240            |

The unstandardized B represents the variation in confinement HADS scores with 1-unit variation in a given predictor

Abbreviations: HADS Hospital Anxiety and Depression Scale, CI confidence interval, SCD-Q Subjective Cognitive Decline Questionnaire

Table 4 Results from the model including Aβ positivity and stress-related measurements

| Predictor                  | Confine HADS | B value (95% CI) | p value |
|----------------------------|--------------|------------------|---------|
| SCD-Q, MyCog scores       | 0.12 (−0.01 to 0.25) | 0.069            |
| Aβ positivity              | 1.95 (0.28 to 3.63) | 0.023            |
| PSS scores                | 0.49 (0.43 to 0.56) | < 0.001          |
| BRS scores                | −0.28 (−1.56 to 1.01) | 0.670            |
| Age, years                | −0.11 (−0.24 to 0.008) | 0.068            |
| Sex (women)               | 1.11 (0.006 to 2.26) | 0.049            |
| Education, years          | −0.12 (−0.28 to 0.033) | 0.120            |
| Pre-confinement HADS      | 0.01 (0.11 to 0.13) | 0.870            |
| Time difference            | 0.4 (−0.17 to 0.98) | 0.170            |

The unstandardized B represents the variation in confinement HADS scores with 1-unit variation in a given predictor

Abbreviations: HADS Hospital Anxiety and Depression Scale, CI confidence interval, Aβ amyloid-beta, SCD-Q Subjective Cognitive Decline Questionnaire, PSS Perceived Stress Scale, BRS Brief Resilience Scale

Unlike continuous SCD-Q scores, SCD status did not show an association with HADS scores during the confinement (95% CI = −0.38 to 2.58, B = 1.10, p = 0.14).

SCD plus criteria—persistent SCD and age at onset of SCD after 60 years old

Given that the SCD-Q and SCD classification was performed based on pre-confinement evaluations, we repeated our main analysis with those participants that have a follow-up evaluation (N = 219) and were classified as SCD (N = 39). Persistent SCD (classified as SCD in both time points) was associated with greater HADS scores irrespective of pre-confinement HADS scores (95% CI = 0.07 to 3.73, B = 1.90, p = 0.042).

In addition, we repeated our models excluding those participants classified as SCD and aged below 60 (N = 27). The main results remained unchanged: the categorical SCD variable did not show a significant association with HADS scores (95% CI = −0.15 to 3.66, B = 1.75, p = 0.071). Higher SCD-Q scores, instead, were associated with confinement HADS scores irrespective of pre-confinement anxiety/depression levels (95% CI = 0.13 to 0.52, B = 0.32, p = 0.001).

Differences in worries and lifestyle changes between participants with SCD that sought medical help vs. those that did not seek medical help

Within the group of participants classified as having SCD, we investigated whether those that sought medical help due to the perceived decline in cognition showed any differences in confinement-related worries and lifestyle changes than the ones that did not seek medical help (Fig. 1B). The rationale behind this sensitivity analysis is that seeking medical help is linked to worrying about the subjective decline in cognition [12, 47]. The two groups did not show any differences in worries about access to primary products (X²(1) = 0.04; p = 0.84), self-protection materials (X²(1) = 1.37; p = 0.24), or economic situation (X²(1) = 0.005; p = 0.94). We also did not observe any differences between the groups in changes in sleep duration (X²(1) = 0.18; p = 0.67), sleep quality (X²(1) = 0.68; p = 0.41), or eating habits (X²(1) = 1.005; p = 0.32) during the confinement.

Models adjusted by the change in sleep duration

We adjusted our main models by the change in sleep duration during the confinement. Following this adjustment, previously reported associations between SCD-Q and HADS scores did not change. Additionally, change in sleep duration showed a significant association with confinement HADS scores irrespective of pre-confinement anxiety/depression levels (95% CI = 1.49 to 5.35, B = 3.42, p < 0.001).

Discussion

In the current study, we investigated the association of the intensity of SCD with anxious/depressive symptoms during the COVID-19-related home confinement in a cohort of CU adults with an elevated risk of developing AD dementia. Our findings showed that higher levels of SCD, as measured by MyCog scores, were associated with presenting greater anxious/depressive symptoms during the COVID-19 confinement, irrespective of the pre-confinement anxiety/depression levels. Furthermore, Aβ positivity and higher stress perception showed independent associations with greater anxiety/depression scores. Mediation analyses revealed that the association of SCD intensity with higher anxiety/depression symptoms was mediated by perceived stress but not Aβ positivity. Lastly, we did not observe any differences in...
worries or lifestyle changes between the participants with or without SCD during the confinement.

During the COVID-19 pandemic, severe restrictions implemented to prevent the spread of the disease had negative effects on people’s mood, lifestyle, and mental health [33, 48]. In line with previous reports [49, 50], our sample showed increases in anxious/depressive symptoms between pre-confinement and confinement measurements. In addition, although the majority of the participants were not diagnosed with anxiety or depression during the confinement, the observed increase in anxiety/depression scores from pre-confinement (1.5 ± 5.8) was within the range of the minimum clinically significant difference suggested for the HADS [51, 52]. While participants having SCD had higher pre-confinement and confinement anxiety/depression scores than the ones without SCD, only the latter showed a minimum clinically significant difference from pre-confinement to confinement (mean change: 1.6 ± 5.9). Previous studies suggested an association of FH of dementia with greater cognitive complaints [53, 54] which could be mediated by depressive symptoms [55]. However, we did not observe any significant differences in HADS in those with and without FH of sporadic AD in our sample. Furthermore, having higher pre-confinement HADS scores independently contributed to explain higher HADS scores during the confinement. These results suggest that home confinement had a global influence on anxious/depressive...
symptomatology, including in individuals without cognitive complaints [2, 7, 36].

In line with our hypothesis, participants having higher levels of SCD showed higher anxious/depressive symptoms during the confinement irrespective of the pre-confinement anxiety/depression levels. These results are consistent with previous studies showing associations between SCD and affective symptoms [26, 56], specifically during the pandemic [3, 6, 7]. Previous studies performed during the pandemic focused on the differences in mental health outcomes between participants with SCD [7] and with mild cognitive impairment (MCI) or AD dementia [3, 6]. A strength of our study, compared to previous work, is that our cohort consisted of CU participants with a subgroup having SCD that allowed us to evaluate the differences in anxious/depressive symptoms between participants without and with SCD considering the intensity of the symptoms. When the categorical SCD variable was considered, having SCD did not show an association with anxiety/depression symptoms. When we performed the analysis using a longitudinal SCD classification (i.e., persistency of SCD over time), persistent SCD status was associated with HADS scores independent of pre-confinement HADS levels. The difference in the results depending on the approach used for SCD could reflect a limitation of using a single general question to determine the SCD status on a single time point. Considering that our main findings are consistent with the previous studies using SCD-Q MyCog scores as a continuous spectrum of SCD-related complaints [26, 40], these results suggest that the intensity of SCD could be a more sensitive approach to capture associations with anxiety/depression in middle-aged adults when only one time point assessment is available.

Our results showed that Aβ positivity measured 2.4 years before the confinement was associated with greater anxious/depressive symptoms during the confinement. These findings are consistent with the literature reporting associations between Aβ pathology and neuropsychiatric symptomatology in cognitively unimpaired older adults [19, 21–23], although the direction of causality between the two events is not clear. Previous studies suggested that anxious/depressive symptoms might facilitate or accelerate the expansion of Aβ and pathological progression of the disease [57, 58]. Conversely, specific neuropsychiatric symptoms, such as anxiety and depression, may represent an early manifestation of AD pathophysiology [23, 59]. Longitudinal studies are required to validate this hypothesis and unravel the potential causal relationship between the two events.

Higher levels of stress are often associated with negative emotions [60] and the development of affective symptoms, in particular during negative life events [61, 62]. The studies conducted during the pandemic suggested that confinement acts as the main stressor having an adverse impact on mental health [33, 35]. In our sample, we found that the association of higher levels of SCD with anxious/depressive symptoms was mediated by self-perceived stress during the confinement. This result is consistent with the reported associations between subjective cognitive complaints and stress perception in older adults [25, 33, 63]. The dysregulation in the hypothalamic-pituitary-adrenal axis may explain these associations such that stress-induced glucocorticoid secretion could have detrimental effects on memory performance [64, 65]. In agreement with these findings, our results suggest that people with higher levels of SCD are more vulnerable to stressors which may hasten the development of negative mental health outcomes. Overall, these findings support the previous research suggesting that interventions targeting stress alleviation can improve mental health outcomes in older adults with SCD [66].

Recent studies observed COVID-19 pandemic-related worries (e.g., related to getting the COVID-19 disease or socio-economic concerns) and lifestyle changes (e.g., changes in sleep or eating habits) in the general population [35, 48, 67] as well as in adults with SCD, MCI, or dementia [3, 6, 7]. We investigated whether the participants classified as SCD presented greater levels of worries and lifestyle changes during the confinement compared to those without SCD. Contrary to our hypothesis, the two groups did not show any differences in worries related to access to primary products, self-protection materials, or economic situation during the confinement. One possible explanation could be that the higher levels of worries observed in individuals with SCD [68] may be specific to cognitive decline-related concerns [12, 47] rather than reflecting a general trait of worrying in this population. However, our assessment did not include worries about the cognitive status during the confinement as in recent studies [3, 69]. Similarly, we did not observe significant differences in changes in sleep duration, sleep quality, or eating habits between the two groups. Previous studies found lower sleep duration [70] or sleep quality [71] in adults with SCD as compared to those without SCD using objective measurements. However, our questionnaire investigating the lifestyle changes was self-reported which could possibly explain the different results.

Lastly, we observed higher anxious/depressive symptoms during the COVID-19 confinement in younger participants and those with fewer years of education. Following the inclusion of Aβ positivity and stress-related measurements, sex (women) also showed an association with higher anxiety/depression scores. Overall, these results are in line with recent studies showing a higher
prevalence of mental health problems in women, younger aged, and lower educated adults during the COVID-19 pandemic [2, 50, 72, 73]. Many studies attributed these findings to financial inequalities, poor economic status, and unemployment that have been shown as risk factors for developing anxiety and depression during the pandemic, particularly in these groups [2, 72]. Moreover, economic uncertainties and associated distress may exacerbate the negative consequences of the pandemic on the mental well-being of these populations in the long term [2, 74].

Limitations
Our study has several limitations. Firstly, our main results are reported on individuals recruited for a research study, and the majority have a FH of sporadic AD, linked previously with greater levels of cognitive complaints [53–55]. However, we did not observe any difference in SCD intensity between participants with or without FH of AD in our sample. Nevertheless, extrapolation to the general SCD population should not be done without further research. Secondly, among the ALFA+ participants that received the invitation to participate in the current study, only 59% of them responded. However, there were no significant differences in demographics or pre-confinement HADS scores between the responders and non-responders (data not shown). Furthermore, although the measurements of anxiety/depression were collected during the COVID-19-related home confinement, we cannot directly attribute the reported anxious/depressive symptoms in SCD to the confinement. Neuropsychiatric symptoms may also appear as part of the preclinical AD process [23, 59]. However, our HADS measurements were associated with the intensity of the confinement. In the same vein, the clinical measurements used in this study were self-reported, and objective measurements may provide different results. Yet, our results are supported by previous studies reporting higher anxiety, depression, or stress in similar cohorts during the confinement using subjective scales [3, 33]. Finally, our participants performed the SCD-Q before the pandemic, and SCD was not assessed during the COVID-19 confinement. Therefore, possible changes in the cognitive status of the participants from pre-confinement to confinement were not evaluated. However, with the available data collected after the confinement, we were able to repeat the main analysis only in the subsample that showed persistent SCD (N=39), and the results remained the same.

Conclusions
Our findings showed that adults at increased risk of AD and with higher levels of SCD are more vulnerable to adverse mental health outcomes during the COVID-19-related confinement. Furthermore, the mental health burden observed in adults with SCD may be mediated by stress perception. These results emphasize the importance of investigating the role of stress management in reducing the affective symptoms in the SCD population that could potentially lower the overall risk of cognitive impairment and dementia in the long term.

Abbreviations
Aβ: Amyloid-beta; AD: Alzheimer’s disease; ALFA: ALzheimer’s and FAmilies; BRS: Brief Resilience Scale; CL: Centiloid; FH: Family history; HADS: Hospital Anxiety and Depression Scale; PET: Positron emission tomography; PSS: Perceived Stress Scale; SCD: Subjective cognitive decline; SCD-Q: Subjective Cognitive Decline Questionnaire.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s13195-022-01068-7.

Additional file 1: Table S1 Selected questions from the online ad-hoc questionnaire on worries and lifestyle changes during the COVID-19 confinement.

Acknowledgements
This publication is part of the ALzheimer’s and FAmilies (ALFA) study. The authors would like to express their sincerest gratitude to ALFA project participants and relatives without whom this research would have not been possible. Collaborators of the ALFA study are Annabella Beteta, Raffaele Cacciaglia, Alba Cañas, Irene Cúmpilido, Ruth Domínguez, Maria Emilio, Carles Falco, Laura Hernández, Gema Huesa, Jordi Huguet, Paula Marine, Tania Menchón, Grégory Operto, Albina Polo, Blanca Rodríguez-Fernández, Sandra Pradas, Iman Sadeghi, Anna Soteras, Laura Stankeviciute, Marc Vilanova, and Natalia Vilor-Tejedor.

Authors’ contributions
Design/conceptualization of the study: EMAU, GSB, and MA. Acquisition, analysis, or interpretation of the data: MA, GSB, ABS, CPG, EP, MS, CD, SFJ, GS, JMD, MSC, CM, KF, JLM, JDG, ORG, and EMAU. Drafting of the manuscript: MA, GSB, and EMAU. Revision of the manuscript and providing critical feedback: all authors. The authors read and approved the final manuscript.

Funding
This research was supported by Alzheimer’s Association research grants (AARG 2019-AARG-644641, AARG 2019-AARG-644641-RAPID) to EMAU. EMAU holds a “Ramón y Cajal” fellowship (RYC2018-026053-I). EMAU holds a grant from the Ministry of Science and Innovation (PID2019-111514RA-I00). The research leading to these results has received funding from the “la Caixa” Foundation (LCF/PR/1710300004), the Alzheimer’s Association, and an international anonymous charity foundation through the TriBEKa Imaging Platform project. Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under grant 2017-SGR-892.

MSC receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (Grant Agreement No. 948677) and the Instituto de Salud Carlos III (PI19/00155) and a fellowship from “la Caixa” Foundation (ID 100101434) and the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 847648 (LCE/RQ/PR21/11840004).

Availability of data and materials
The data supporting the results of the current study are not publicly available but may be available upon a reasonable request.
Declarations

Ethics approval and consent to participate
The ALFA+ study protocol and informed consent were approved by the Independent Ethics Committee “Parc de Salut Mar” (ALFA-FPM-0311) and registered at ClinicalTrials.gov (Identifier: NCT02485730). The COVID-19 protocol (CovidImpact_BBRC2020) was approved on March 16, 2020 (2020/9255). The informed consent for the COVID-19 study was obtained from all participants via an online form. All methods were carried out in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

Consent for publication
NA.

Competing interests
MSC has served as a consultant and on advisory boards for Roche Diagnostics International Ltd. and has given lectures in symposia sponsored by Roche Diagnostics, S.L.U, and Roche Farma, S.A.

Author details
1. BarcelonàsBeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain. 2. Universitat Pompeu Fabra, Barcelona, Spain. 3. IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain. 4. Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES), Madrid, Spain. 5. Global Brain Health Institute, University of California San Francisco, San Francisco, CA, USA. 6. Department of Clinical Sciences, Clinical Memory Research Unit, Malmo, Sweden. 7. Servei de Neurologia, Hospital del Mar, Barcelona, Spain. 8. H. Lundbeck A/S, Copenhagen, Denmark. 9. Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Madrid, Spain.

Received: 18 February 2022   Accepted: 28 August 2022
Published online: 06 September 2022

References
1. Nochaiwong S, Ruengorn C, Thavorn K, et al. Global prevalence of mental health issues among the general population during the coronavirus disease-2019 pandemic: a systematic review and meta-analysis. Sci Rep. 2021;11(1):10173. https://doi.org/10.1038/s41598-021-89700-8.
2. Xiong J, Lipsitz O, Nair F, et al. Impact of COVID-19 pandemic on mental health in the general population: a systematic review. J Affect Disord. 2020;277:55–64. https://doi.org/10.1016/j.jad.2020.08.001.
3. van Maurik IS, Bakker ED, van den Buuse S, et al. Psychosocial effects of home confinement on mental health in individuals with increased risk of mental health of vulnerable populations. Acta Biomed. 2020;91, 95(9–10):1522–33. https://doi.org/10.23750/abm.v91i9‑10.1522.
4. Studart A, Nitrini R. Subjective cognitive decline: the first clinical manifestation of Alzheimer’s disease? Dement Neuropsychol. 2016;10(3):170–7. https://doi.org/10.1590/1980‑5764‑2016D N1003007.
5. Jenkins A, Tree J, Tales A. Distinct profile differences in subjective cognitive symptoms: a systematic review. Gerontologist. 2016;56(6):e109–27. https://doi.org/10.1093/geront/njw091.
6. Jessen F, Amargilo RE, van Bodegom M, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease. Alzheimers Dement. 2014;10(6):844–52. https://doi.org/10.1016/j. jad.2014.01.001.
7. Nozawa K, Akimoto H, Nakamura M, et al. Mild cognitive impairment in at‑risk groups for AD dementia and their association with worry and AD biomarkers—results from the DELCODE study. Alzheimers Res Ther. 2020;12(1):131. https://doi.org/10.1186/s13195‑020‑00701‑7.
8. Sannemann L, Schild AK, Altenstein S, et al. Neuropsychiatric symptoms and subjective cognitive decline in elderly patients: the Mayo Clinic Study of Aging. Int Psychogeriatr. 2018;30(2):245–51. https://doi.org/10.1017/ipg.2017.002.
9. Hill NL, Mogle J, Wion R, et al. Subjective cognitive impairment and affective symptoms: a systematic review. Gerontologist. 2016;56(6):e109–27. https://doi.org/10.1093/geront/nGW091.
10. Jenkins A, Tree J, Tales A. Distinct profile differences in subjective cognitive decline in the general public are associated with metacognition, negative affective symptoms, neuroticism, stress, and poor quality of life. J Alzheimers Dis. 2021;80(3):1231–42. https://doi.org/10.3233/JAD‑200190.
11. Sannemann L, Schild AK, Altenstein S, et al. Neuropsychiatric symptoms and subjective cognitive decline in elderly persons: the Mayo Clinic Study of Aging. Int Psychogeriatr. 2018;30(2):245–51. https://doi.org/10.1017/ipg.2017.002.
12. Jessen F, Amargilo RE, van Bodegom M, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease. Alzheimers Dement. 2014;10(6):844–52. https://doi.org/10.1016/j. jad.2014.01.001.
13. Molinuevo JL, Rabl LA, Amargilo R, et al. Implementation of subjective cognitive decline criteria in research studies. Alzheimers Dement. 2017;13(3):296–311. https://doi.org/10.1016/j. jad.2017.09.012.
14. Jessen F. Subjective and objective cognitive decline at the pre‑dementia stage of Alzheimer’s disease. Eur Arch Psychiatry Clin Neurosci. 2014;264(1):3–7. https://doi.org/10.1007/s00406‑014‑0539‑2.
15. Studart A, Nitrini R. Subjective cognitive decline: the first clinical manifestation of Alzheimer’s disease? Dement Neuropsychol. 2016;10(3):170–7. https://doi.org/10.1590/1980‑5764‑2016D N1003007.
16. Perrotin A, Mormino EC, Madison CM, Hayenga AG, Jagust WJ. Subjective cognitive and amyloid deposition imaging: a Pittsburgh Compound B positron emission tomography study in normal elderly individuals. Arch Neurol. 2012;69(2):223–9. https://doi.org/10.1001/archneur.2011.666.
17. Sitzer BE, Lopez CL, McCade E, et al. Amyloid-beta imaging in older adults presenting to a memory clinic with subjective cognitive decline: a pilot study. J Alzheimers Dis. 2015;48(Suppl 1):S151–9. https://doi.org/10.3233/JAD‑1501113.
18. Ang YJ, Ho JK, Blanken AE, Dutt S, Nation DA. Affective neuropsychiatric symptoms as early signs of dementia risk in older adults. J Alzheimers Dis. 2020;77(3):1195–207. https://doi.org/10.3233/JAD‑200190.
19. Lavretsky H, Siddarth P, Kepe V, et al. Depression and anxiety symptoms are associated with cerebral FDG‑PET binding in middle‑aged and older non‑demented adults. Am J Geriatr Psychiatry. 2009;17(6):493–502. https://doi.org/10.1097/jgp.0b013e3181953b82.
20. Babulal GM, Ghoshal N, Head D, et al. Mood changes in cognitively normal older adults are linked to Alzheimer disease biomarker levels. Am J Geriatr Psychiatry. 2016;24(11):1095–104. https://doi.org/10.1016/j.jagp.2016.04.004.
21. Sannemann L, Schild AK, Altenstein S, et al. Neuropsychiatric symptoms in at‑risk groups for AD dementia and their association with worry and AD biomarkers—results from the DELCODE study. Alzheimers Res Ther. 2020;12(1):131. https://doi.org/10.1186/s13195‑020‑00701‑7.
22. Krell‑Roesch J, Lowe VJ, Neureiter J, et al. Depressive and anxiety symptoms and cortical amyloid deposition among cognitively normal elderly persons: the Mayo Clinic Study of Aging. Int Psychogeriatr. 2018;30(2):245–51. https://doi.org/10.1017/ipg.2017.002.
23. Donovan NJ, Locascio JJ, Marshall GA, et al. Longitudinal association of amyloid beta and anxio‑ depressive symptoms in cognitively normal older adults. Am J Psychiatry. 2018;175(6):530–7. https://doi.org/10.1176/appi.ajp.2017.17040442.
24. Hill NL, Mogle J, Wion R, et al. Subjective cognitive impairment and affective symptoms: a systematic review. Gerontologist. 2016;56(6):e109–27. https://doi.org/10.1093/geront/nGW091.
25. Jenkins A, Tree J, Tales A. Distinct profile differences in subjective cognitive decline in the general public are associated with metacognition, negative affective symptoms, neuroticism, stress, and poor quality of life. J Alzheimers Dis. 2021;80(3):1231–42. https://doi.org/10.3233/JAD‑200882.
26. Fivush IM, Lu K, Keuss SE, et al. Subjective cognitive complaints at age 70: associations with amyloid and mental health. J Neurol Neuropsychiatry. 2021;24. https://doi.org/10.1136/jnnp‑2020‑325620.
27. Pietrzak RH, Maruff P, Woodward M, et al. Mild worry symptoms predict decline in learning and memory in healthy older adults. Am J Geriatr Psychiatry. 2012;20(3):266–75. https://doi.org/10.1097/JG.P.0b013e318210fe24.
28. Liew TM. Subjective cognitive decline, anxiety symptoms, and the risk of mild cognitive impairment and dementia. Alzheimers Dement. 2020;16(5):e036611. https://doi.org/10.1002/alz.036611.

29. Desai R, Whitfield T, Said G, et al. Affective symptoms and risk of progression to mild cognitive impairment or dementia in subjective cognitive decline: a systematic review and meta-analysis. Ageing Res Rev. 2021;71:101419. https://doi.org/10.1016/j.arr.2021.101419.

30. Hill NL, Bhargava S, Bratlee-Whitaker E, Turner JR, Brown MJ, Mogle J. Longitudinal relationships between subjective cognitive decline and objective memory: depressive symptoms mediate between-person associations. J Alzheimers Dis. 2021;20. https://doi.org/10.3233/JAD-210230.

31. Wang SM, Do Han K, Kim NY, et al. Late-life depression, subjective cognitive decline, and their additive risk in incidence of dementia: a nationwide longitudinal study. PLoS One. 2021;16(7):e0254639. https://doi.org/10.1371/journal.pone.0254639.

32. Jacob L, Haro JM, Koyanagi A. Physical multimorbidity and subjective cognitive complaints among adults in the United Kingdom: a cross-sectional community-based study. Sci Rep. 2019;9(1):12417. https://doi.org/10.1038/s41598-019-48894-8.

33. Podlesek A, Komidar L, Kavcic V. The relationship between perceived stress and subjective cognitive decline during the COVID-19 epidemic. Front Psychol. 2021;12:647971. https://doi.org/10.3389/fpsyg.2021.647971.

34. Xin M, Luo S, She R, et al. Negative cognitive and psychological correlates of mandatory quarantine during the initial COVID-19 outbreak in China. Am Psychol. 2020;75(7):607–17. https://doi.org/10.1037/amp0000692.

35. Stanton R, To QG, Khalesi S, et al. Depression, anxiety and stress during COVID-19: associations with changes in physical activity, sleep, tobacco and alcohol use in Australian adults. Int J Environ Res Public Health. 2020;17(11):4065. https://doi.org/10.3390/ijerph17114065.

36. Manca R, De Marco M, Vennieri A. The impact of COVID-19 infection and enforced prolonged social isolation on neuropsychiatric symptoms in older adults with and without dementia: a review. Front Psychiatry. 2020;11:585540. https://doi.org/10.3389/fpsyg.2020.585540.

37. Molinuevo JL, Gramunt N, Gispert JD, et al. The ALFA project: a research platform to identify early pathophysiological features of Alzheimer’s disease. Alzheimers Disease (N Y). 2016;3:62–92. https://doi.org/10.1016/trci.2016.02.003.

38. Arenaza-Urquijo EM, Salvador G, Otero G, et al. Association of years to parent’s sporadic onset and risk factors with neural integrity and Alzheimer biomarkers. Neurology. 2020;95(15):e2065–74. https://doi.org/10.1212/WNL.00000000000010527.

39. Ministro de Sanidad. Orden SND/399/2020, de 9 de Mayo, Para La Establecidas Tras La Declaración Del Estado de Alarma En Aplicación de La Fase 1 Del Plan Para La Transición Hacia Una Nueva Normalidad. Vol 2020;25(10):2599–607. https://doi.org/10.1038/s41390-019-0214-2.

40. Peters ME, Lyketsos CG. Beyond memory: a focus on the other neuropsychiatric symptoms of dementia. Am J Geriatr Psychiatry. 2015;23(2):115–8. https://doi.org/10.1016/j.jagp.2014.11.002.

41. Sánchez-Benavides G, Suárez-Calvet M, Milà-Alomà M, et al. Amyloid-β positive individuals with subjective cognitive decline present increased risk of mild cognitive impairment or dementia in subjective cognitive decline during the COVID-19 pandemic: longitudinal analyses of adults in the UK COVID-19 Mental Health & Wellbeing study. Br J Psychiatry. 2020;211:1–8. https://doi.org/10.1192/bjp.bp.2020.212.

42. Canet G, Hernandez C, Zussy C, Chevallier N, Desrumaux C, Givalois L. Is AD a stress-related disorder? Focus on the HPA axis and its promising role in the pathogenesis of Alzheimer’s disease. J Alzheimers Dis. 2022;11. https://doi.org/10.3233/JAD-2215416.

43. Hill NL, Bhargava S, Bratlee-Whitaker E, Turner JR, Brown MJ, Mogle J. Subjective cognitive decline, anxiety symptoms, and their additive risk in incidence of dementia: a nationwide longitudinal study. PLoS One. 2021;16(7):e0254639. https://doi.org/10.1371/journal.pone.0254639.

44. Smith BW, Dalen J, Wiggins K, Tooley E, Christopher P, Bernard J. The brief resilience scale: assessing the ability to bounce back. Int J Behav Med. 1983;24(4):385–96. https://doi.org/10.2307/2136404.

45. Semple CF, McKenzie A, McNeil R, et al. Mental health and subjective cognitive decline among older adults with chronic obstructive pulmonary disease. Health Qual Life Outcomes. 2008;6:46. https://doi.org/10.1186/1477-7525-6-46.

46. Mogle J. How the brain adapts to stress and subjective cognitive decline during the COVID-19 epidemic. Front Psychol. 2021;12:647971. https://doi.org/10.3389/fpsyg.2021.647971.

47. Ammar A, Trabelsi K, Brach M, et al. Effects of home confinement on mental health and lifestyle behaviours during the COVID-19 outbreak: insights from the ECLB-COVID19 multicentre study. Br J Sport. 2021;38(19):1–21. https://doi.org/10.1111/bjsport.2020.96857.

48. Potter GG, Hartman M, Reed JL. Establishing the minimal clinically important difference of the hospital anxiety and depression scale in patients with cardiovascular disease. J Cardiopulm Rehabil Prev. 2019;39(6):E6–E11. https://doi.org/10.1097/HCR.0000000000000379.

49. Xin M, Luo S, She R, et al. Negative cognitive and psychological correlates of mandatory quarantine during the initial COVID-19 outbreak in China. Am Psychol. 2020;75(7):607–17. https://doi.org/10.1037/amp0000692.

50. O’Connor RC, Wetherall K, Cleare S, et al. Mental health and well-being during the COVID-19 pandemic: longitudinal analyses of adults in the UK COVID-19 Mental Health & Wellbeing study. Br J Psychiatry. 2020;211:1–8. https://doi.org/10.1192/bjp.bp.2020.212.

51. Cahn I, Mocquard A, Kermarrec L, et al. Positive individuals with subjective cognitive decline present increased risk of mild cognitive impairment or dementia in subjective cognitive decline during the COVID-19 epidemic: longitudinal analyses of adults in the UK COVID-19 Mental Health & Wellbeing study. Br J Psychiatry. 2020;211:1–8. https://doi.org/10.1192/bjp.bp.2020.212.
therapeutic targets. Front Aging Neurosci. 2019;11:269. https://doi.org/10.3389/fnagi.2019.00269.
66. Marchant NL, Barnhofer T, Klimcik OM, et al. The SCD-Well randomized controlled trial: effects of a mindfulness-based intervention versus health education on mental health in patients with subjective cognitive decline (SCD). Alzheimers Dement (N Y). 2018;4:737–45. https://doi.org/10.1016/j.trci.2018.10.010.
67. Reppas-Rindlisbacher C, Finlay JM, Mahar AL, et al. Worries, attitudes, and mental health of older adults during the COVID-19 pandemic: Canadian and U.S. perspectives. J Am Geriatr Soc. 2021;69(5):1147–54. https://doi.org/10.1111/jgs.17105.
68. Schwarz C, Lange C, Benson GS, et al. Severity of subjective cognitive complaints and worries in older adults are associated with cerebral amyloid-β load. Front Aging Neurosci. 2021;13:67583. https://doi.org/10.3389/fnagi.2021.67583.
69. Bakker ED, van Maurik IS, Mank A, et al. Psychosocial effects of COVID-19 measures on (pre-)dementia patients during second lockdown. J Alzheimers Dis. 2022;86(2):931–9. https://doi.org/10.3233/JAD-215342.
70. Bubbico G, Di Iorio A, Lauriola M, et al. Subjective cognitive decline and nighttime sleep alterations, a longitudinal analysis. Front Aging Neurosci. 2019;11:142. https://doi.org/10.3389/fnagi.2019.00142.
71. Lauriola M, Esposito R, Pizzi SD, et al. Sleep changes without medial temporal lobe or brain cortical changes in community-dwelling individuals with subjective cognitive decline. Alzheimers Dement. 2017;13(7):783–91. https://doi.org/10.1016/j.jalz.2016.11.006.
72. Varma P, Junge M, Meaklim H, Jackson ML. Younger people are more vulnerable to stress, anxiety and depression during COVID-19 pandemic: a global cross-sectional survey. Prog Neuro-Psychopharmacol Biol Psychiatry. 2021;109:10236. https://doi.org/10.1016/j.pnpbp.2020.10236.
73. Benke C, Autenrieth JK, Asselmann E, Pané-Fané CA: Lockdown, quarantine measures, and social distancing: associations with depression, anxiety and distress at the beginning of the COVID-19 pandemic among adults from Germany. Psychiatry Res. 2020;293:113462. https://doi.org/10.1016/j.psychres.2020.113462.
74. Ng KH, Agius M, Zaman R. The global economic crisis: effects on mental health and what can be done. J R Soc Med. 2013;106(6):211–4. https://doi.org/10.1177/0141076813481770.

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.